Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
| Autor: | B, Combe, C, Codreanu, U, Fiocco, M, Gaubitz, P P, Geusens, T K, Kvien, K, Pavelka, P N, Sambrook, J S, Smolen, R, Khandker, A, Singh, J, Wajdula, S, Fatenejad, Horatiu, Bolosiu |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Adolescent Immunology Arthritis Receptors Tumor Necrosis Factor General Biochemistry Genetics and Molecular Biology Etanercept law.invention Arthritis Rheumatoid Young Adult Pharmacotherapy Double-Blind Method Rheumatology Randomized controlled trial immune system diseases Sulfasalazine law Internal medicine medicine Humans Immunology and Allergy skin and connective tissue diseases Aged business.industry Middle Aged Clinical and Epidemiological Research medicine.disease Surgery stomatognathic diseases Regimen Treatment Outcome Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/ard.2007.087106 |
| Popis: | Objective: To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy. Methods: Patients were randomly assigned to etanercept (25 mg twice weekly; sulfasalazine was discontinued at baseline), etanercept plus sulfasalazine (unchanged regimen of 2–3 g/day) or sulfasalazine in a double-blind, randomised, 2-year study in adult patients with active RA despite sulfasalazine therapy. Efficacy was assessed using the American College of Rheumatology criteria, disease activity scores (DAS) and patient-reported outcomes (PRO). Results: Demographic variables and baseline disease characteristics were comparable among treatment groups; mean DAS 5.1, 5.2 and 5.1 for etanercept (n = 103), etanercept plus sulfasalazine (n = 101) and sulfasalazine (n = 50), respectively. Withdrawal due to lack of efficacy was highest with sulfasalazine (26 (52%) vs 6 (6%) for either etanercept group, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|